Laterre, Pierre-François
Pickkers, Peter
Marx, Gernot
Wittebole, Xavier
Meziani, Ferhat
Dugernier, Thierry
Huberlant, Vincent
Schuerholz, Tobias
François, Bruno
Lascarrou, Jean-Baptiste
Beishuizen, Albertus
Oueslati, Haikel
Contou, Damien
Hoiting, Oscar
Lacherade, Jean-Claude
Chousterman, Benjamin
Pottecher, Julien
Bauer, Michael
Godet, Thomas
Karakas, Mahir
Helms, Julie
Bergmann, Andreas
Zimmermann, Jens
Richter, Kathleen
Hartmann, Oliver
Pars, Melanie
Mebazaa, Alexandre http://orcid.org/0000-0001-8715-7753
Castanares, Diego
Collienne, Christine
Gèrards, Ludovic
Hantson, Phillipe
Montiel, Virginie
Berghe, Caroline
Dujardin, Marie-France
Gielens, Leslie
Renard, Suzanne
Jorens, Philippe
Asfar, Pierre
Plantefève, Gaëtan
Duranteau, Jacques
Weiss, Emmanuel
Vuillard, Constance
Fedou, Anne-Laure
Goudelin, Marine
Evrard, Bruno
Daix, Thomas
Desachy, Arnaud
Vignon, Philippe
Duchambon, Anne-Aurore
Baudrillart, Ludmila
Bourzeix, Paul
Gay, Alexandra
Prevost, Céline
Chalot, Coralie
Herafa, Isabelle
Engels, Perrine
Maëlle, Martin
Abeud, Lila-Fariza
Berton, Laure
Cerlinskaite, Kamile
Deye, Nicolas
Fournier, Marie-Celine
Hadjam, Tassadit
Hollinger, Alexa
Javanainen, Tuija
Jourdaine, Clement
Legrand, Matthieu
Louadah, Badr
Neuschwander, Arthur
Clere-Jehl, Raphaël
Demiselle, Julien
Merdji, Hamid
Monnier, Alexandra
Mercier, Emmanuelle
Kluge, Stefan
Zarbock, Alexander
van Zanten, Arthur R. H.
Vermeijden, Wytze
Dormans, Tom
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial
https://doi.org/10.1007/s00134-021-06537-5
A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2) (Pre-results)
https://doi.org/10.1136/bmjopen-2018-024475
Funding for this research was provided by:
Adrenomed AG
Article History
Received: 12 May 2021
Accepted: 9 September 2021
First Online: 4 October 2021
Declarations
:
: P-F L received fees as a coordinator of the CCC. PP reports travel and consultancy reimbursement from Adrenomed, SphingoTec, 4TEEN4, AM-Pharma, Baxter, EBI. XW was part of the Clinical Coordinating Center assessing patient’s eligibility. No other conflict of interest. FM has no conflict of interest. TD received fees as a coordinator of the CCC. BF reports personal fees outside the submitted work from Inotrem, Biomérieux, AM-Pharma, Takeda, Enlivex, Aridis, GSK, Asahi-Kasai. JBL reported receiving consultation fees from Asahi Kasei America Corporation outside the submitted work. AB Consultancy fees from GSK and Danone Nutricia. DC has no conflict of interest. OH has no conflict of interest. JCL has no conflict of interest to declare. BC served as a member of an advisory board for Roche Diagnostics. JP has no conflict of interest with the present work. MB holds shares of SmartDyeLivery GmbH, Jena. He has received funding for scientific advisory boards, travel and speaker honoraria by T2 Biosystems, Inc., La Jolla Pharmaceutical Company, SNIPR BIOME Denmark, CytoSorbents GmbH, Thermo Fisher Scientific (B·R·A·H·M·S GmbH), Roche Diagnostics International Ltd., Transgene S.A. and SphingoTec GmbH. TG has non conflict of interest with the present work. MK reports grant support from Adrenomed and Vifor, and honoraria from Adrenomed, SphingoTec, Vifor, Amgen, 4TEEN4, Astra-Zeneca, and Sanofi. AM reports personal fees from Orion, Sanofi, Adrenomed, Epygon and Fire 1 and grants and personal fees from 4TEEN4, Abbott, Roche and SphingoTec.
Free to read: This content has been made available to all.